Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents-Reference-Cited by-同舟云学术

Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents

Published:2017-08-08 Issue:10 Volume:11 Page:791-805
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Puri Sonam¹,Chatwal Monica¹,Gray Jhanelle E²

Affiliation:

1. Department of Hematology and Oncology, H. Lee Moffitt Cancer Center and Research Institute/ University of South Florida, Tampa, FL, USA

2. Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2017.1361323

Reference91 articles.

1. SEER Cancer Statistics Factsheets, Lung and Bronchus, National Cancer Institute, Bethesda, MD, [cited 2017 10 April]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html

2. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

3. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

4. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

5. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression;Journal of Cancer Research and Clinical Oncology;2022-07-30

2. Hypoxic bone marrow mesenchymal cell‐extracellular vesicles containing miR‐328‐3p promote lung cancer progression via the NF2‐mediated Hippo axis;Journal of Cellular and Molecular Medicine;2020-11-21

3. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer;Drug Resistance Updates;2019-09

4. Overexpressed D2 Dopamine Receptor Inhibits Non-Small Cell Lung Cancer Progression through Inhibiting NF-κB Signaling Pathway;Cellular Physiology and Biochemistry;2018